Takeda Pharmaceutical Company Limited (NYSE:TAK) shares traded 1.37% higher at $15.56 on Wall Street last session.
In accordance with the data, 19 analysts cover Takeda Pharmaceutical Company Limited (NYSE:TAK). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.69 and a low of $12.80, we find $16.52. Given the previous closing price of $15.35, this indicates a potential upside of 7.62 percent. TAK stock price is now -2.59% away from the 50-day moving average and 0.89% away from the 200-day moving average. The market capitalization of the company currently stands at $48.84B.
It has been rated a hold by 12 analysts and a buy by 6. Brokers who have rated the stock have averaged $16.65 as their price target over the next twelve months.
With the price target maintained at $20, BofA Securities recently Upgraded its rating from Neutral to Buy for Takeda Pharmaceutical Company Limited (NYSE: TAK).
There have been several recent changes in the stakes of large investors in TAK stock. A new stake in Takeda Pharmaceutical Company Limited shares was purchased by CAPRICORN FUND MANAGERS LTD during the first quarter worth $13,513,000. KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC invested $7,364,000 in shares of TAK during the first quarter. In the first quarter, D. E. SHAW & CO., INC. acquired a new stake in Takeda Pharmaceutical Company Limited valued at approximately $6,386,000. QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in TAK for approximately $5,242,000. PSAGOT VALUE HOLDINGS LTD. / (ISRAEL) purchased a new stake in TAK valued at around $2,712,000 in the second quarter. In total, there are 337 active investors with 2.10% ownership of the company’s stock.
Takeda Pharmaceutical Company Limited (NYSE: TAK) opened at $15.54 on Friday. During the past 12 months, Takeda Pharmaceutical Company Limited has had a low of $12.28 and a high of $17.15. As of last week, the company has a debt-to-equity ratio of 0.69, a current ratio of 1.00, and a quick ratio of 0.60. According to the stock market information, the enterprise value for the company is $76.13B, which is based on a 21.49 price-to-earnings ratio, a 268.65 price-to-earnings-growth ratio, and a beta of 0.65. The fifty day moving average price for TAK is $15.94 and a two-hundred day moving average price translates $15.44 for the stock.
The latest earnings results from Takeda Pharmaceutical Company Limited (NYSE: TAK) was released for Mar, 2023. The net profit margin was 7.90% and return on equity was 5.00% for TAK. The company reported revenue of $7.31 billion for the quarter, compared to $7.5 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.54 percent.
Moreover, the firm recently paid out its quarterly dividend on 12/12/2022. Investors who held shares on 09/30/2022 were paid a $0.329553 dividend. On an annualized basis, this represents a $0.97 dividend and a 6.23% percent yield. There was an ex-dividend date of 09/29/2022 for this dividend. In terms of dividend payout ratio, TAK is presently at 88.62%.
Takeda Pharmaceutical Company Limited(TAK) Company Profile
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, JCR Pharmaceuticals, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
